🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Mettler-Toledo International Inc. MTD SPXR3KPHARMA

Healthcare · Diagnostics & Research · Switzerland
https://www.mt.com
Company Profile ↓
$1,345.26
+1.60% 1Y
Mkt Cap$26.95B
P/E30.34
P/B2,233.53
52W High$1,506.02
52W Low$1,025.53
Book Value$0.64
EPS (TTM)$44.34

Company Overview

Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other Operations. The company offers laboratory instruments, such as laboratory balances, liquid pipetting solutions, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, density and refractometry instruments, and thermal analysis systems; and other analytical instruments, including UV/VIS spectrophotometers, moisture analyzers, and cell counters, as well as LabX, a laboratory software platform to manage and analyze data generated by its instruments and automate workflows. It also provides industrial instruments comprising industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detectors, x-ray systems, checkweighers, and camera-based imaging equipment. In addition, the company offers retail weighing solutions consisting of weighing and software solutions, AI-driven image recognition solutions for fresh goods, and automated packaging and labeling solutions for the meat backroom. The company serves pharmaceutical and biotech companies, independent research organizations, and testing labs; food manufacturers and retailers; chemical, specialty chemicals, and cosmetics companies; transportation and logistics, metals, and electronics industries; and academic community through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is headquartered in Greifensee, Switzerland.

Why Investors Should Care

Healthy Margins

Maintains a net profit margin of 21.9%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $4.03B (+4.0% YoY); net profit $869.19M.
  • Trailing 12 Months Year-on-year growth — revenue +4.5%, earnings +18.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 4.3%, profit CAGR 8.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:4.28%
1 Year:4.50%

Compounded Profit Growth

5 Years:8.94%
1 Year:18.30%

Stock Price Performance

1 Year:+1.60%
6 Months:+11.21%
3 Months:+16.54%
1 Month:-5.35%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 67% of range
$1,025.53 $1,506.02
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • Golden Cross9d ago
  • RSI (14)38.73 · Neutral
Price Performance
1M-5.35%
3M+16.54%
6M+11.21%
1Y+1.60%
Valuation vs Sector

P/E of 30.34 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Excellent profit margin of 21.9%.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
30.34
Industry PE
25.17
Forward P/E
26.02
PEG Ratio
2.90
Book Value
$0.64
Price to Book
2,233.53
P/S
6.93
EV/EBITDA
24.09
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
4.28%
Profit 5Y
8.94%
Revenue (YoY)
4.50%
Earnings (YoY)
18.30%

Profitability & Returns

ROCE
-
ROE
-
ROA
21.10%
Profit Margin
21.91%
Op Margin
31.20%
Gross Margin
60.26%
EPS (Latest Qtr)
$11.55
EPS (TTM)
$44.34

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
0.66
Current Ratio
1.12
Debt
$2.14B
Total Assets
$3.67B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
0.44%
Chg in Prom Hold
0.00%
FII / Inst Holding
105.59%
Chg in FII Hold
0.03%

Financial Snapshot

Enterprise Value
$26.95B
Total Revenue (TTM)
$4.13B
EBITDA
$1.28B
Free Cash Flow
$693.59M
Operating Cash Flow
$975.17M
Shares Outstanding
20.04M
Gross Margin
60.26%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MTD Mettler-Toledo International Inc. SPXR3KPHARMA 1,345.26 30.34 $26.95B 0.00% - - 4.28% 8.94%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue ---------660.82M722.00M734.85M-679.45M731.37M753.87M-649.16M690.67M807.36M-804.39M924.35M951.95M-897.79M978.39M985.85M-928.74M982.12M942.46M925.95M946.75M954.53M883.74M983.22M1.03B947.13M1.03B
Gross Profit 390.75M299.91M347.58M369.49M418.61M343.39M375.61M400.98M455.77M374.93M412.62M419.25M477.57M388.32M419.54M435.06M498.30M374.41M397.97M469.61M559.04M471.70M536.90M555.82M-519.59M571.66M584.66M-546.57M583.54M559.54M548.13M565.67M572.47M525.88M579.88M609.46M555.82M650.22M
Net Income 123.35M65.67M79.59M101.33M137.78M92.47M101.58M104.95M76.98M93.30M111.47M126.65M181.19M111.81M127.16M129.40M192.75M98.11M126.56M161.77M149.66M149.66M184.76M203.69M174.00M174.00M212.07M220.60M188.43M188.43M213.93M201.63M177.51M221.81M211.52M163.59M202.35M217.49M169.45M232.90M
Diluted EPS 4.442.402.933.775.173.483.843.992.933.584.314.937.114.425.065.207.844.035.226.689.036.327.858.71-7.559.299.76-8.479.699.218.2410.379.967.819.7610.578.3311.55
R&D Expense -28.97M30.70M30.14M-31.20M32.58M32.20M-34.71M35.31M34.84M-36.05M36.58M36.02M-34.39M31.19M34.66M-39.27M42.60M42.28M-43.03M44.02M44.13M-45.48M47.24M46.13M46.41M45.77M47.12M46.35M49.28M51.14M51.27M52.99M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 1.97B1.73B1.97B2.31B2.34B2.38B2.49B2.40B2.51B2.73B2.94B3.01B3.09B3.72B3.92B3.79B3.87B4.03B
Gross Profit 993.08M889.34M1.04B1.22B1.24B1.28B1.36B1.35B1.44B1.58B1.68B1.74B1.80B2.17B2.31B2.24B2.33B2.39B
Net Income 202.78M172.59M232.15M269.49M290.85M306.09M338.24M352.82M384.37M375.97M512.61M561.11M602.74M768.99M872.50M788.78M863.14M869.19M
Diluted EPS 5.795.036.808.219.149.9611.4412.4814.2214.2419.8822.4724.9132.7838.4135.9040.4842.05
R&D Expense 102.28M89.69M97.03M116.14M112.53M116.35M123.30M119.08M119.20M128.31M141.07M143.95M140.10M169.77M177.12M185.28M189.36M199.37M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --1.72B2.28B2.11B2.02B2.15B1.97B1.96B2.17B2.55B2.62B2.79B2.81B3.33B3.49B3.36B3.24B3.71B
Total Equity 581.29M503.25M711.14M771.58M781.14M827.22M935.05M719.60M580.46M434.94M547.28M590.06M420.78M282.68M171.42M24.79M-149.94M-126.89M-23.64M
Cash & Equivalents 81.22M78.07M85.03M447.58M235.60M101.70M111.87M85.26M98.89M158.67M148.69M178.11M207.78M94.25M98.56M95.97M69.81M--
Long Term Debt --203.59M670.30M476.71M347.13M395.96M335.79M575.14M875.06M960.17M985.02M1.24B1.28B1.58B1.91B1.89B1.83B2.09B
Total Liabilities --1.01B1.51B1.42B1.20B1.22B1.29B1.38B1.73B2.00B2.03B2.37B2.53B3.16B3.47B3.51B3.37B3.74B
Current Liabilities --494.68M542.19M609.84M561.99M564.19M678.89M558.21M587.51M689.67M734.43M754.51M840.33M1.15B1.15B1.18B1.17B1.20B

Cash Flows (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 223.15M232.60M268.28M280.88M327.70M345.93M418.91M439.80M460.76M516.33M565.00M603.45M724.70M908.83M859.07M965.87M968.35M955.77M
Investing Cash Flow -48.70M-72.58M-77.02M-132.29M-97.26M-86.02M-94.32M-100.75M-231.46M-217.34M-138.94M-99.08M-100.36M-314.11M-139.40M-131.69M-119.46M-193.87M
Financing Cash Flow -178.53M-157.44M167.92M-360.47M-366.40M-249.89M-348.23M-319.96M-163.60M-319.53M-388.02M-477.37M-743.91M-590.55M-716.04M-859.59M-855.98M-755.17M
Capital Expenditure -61.01M-60.04M-73.94M-98.50M-95.59M-82.35M-89.39M-82.51M-123.96M-127.43M-142.73M-97.34M-92.49M-107.58M-121.24M-105.32M-103.90M-107.12M
Free Cash Flow 162.14M172.56M194.34M182.38M232.12M263.58M329.52M357.29M336.80M388.90M422.28M506.11M632.21M801.25M737.83M860.55M864.45M848.65M
Share Buybacks 229.67M5.99M240.00M204.58M278.67M294.98M414.00M494.97M499.99M400.00M475.00M775.00M775.00M1,000.00M1.10B900.00M850.00M800.00M

Ratios (Annual)

Figures in %.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 50.3%51.4%52.7%52.8%53.0%53.9%54.7%56.4%57.3%57.8%57.4%57.9%58.4%58.4%58.9%59.2%60.1%59.4%
Operating Margin % ------------------
Net Margin % 10.3%10.0%11.8%11.7%12.4%12.9%13.6%14.7%15.3%13.8%17.5%18.6%19.5%20.7%22.3%20.8%22.3%21.6%
ROE % 40.3%24.3%30.1%34.5%35.2%32.7%47.0%60.8%88.4%68.7%86.9%133.3%213.2%448.6%3,519.1%-526.1%-680.2%-3,677.4%
ROCE % ------------------

Shareholding Pattern

Insiders
0.44%
Institutions
105.59%
Public Float
106.05%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 9.39% 1.88M $2.63B
2 Capital International Investors 7.59% 1.52M $2.13B
3 Vanguard Capital Management LLC 6.59% 1.32M $1.85B
4 Vanguard Portfolio Management LLC 5.04% 1.01M $1.41B
5 State Street Corporation 4.75% 951.68K $1.33B
6 T. Rowe Price Investment Management, Inc. 3.47% 694.42K $971.21M
7 Alliancebernstein L.P. 3.39% 679.10K $949.78M
8 Geode Capital Management, LLC 3.06% 612.15K $856.14M
9 Bank Of New York Mellon Corporation 2.98% 596.91K $834.82M
10 Morgan Stanley 2.32% 465.23K $650.66M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MTD

Yahoo Finance Fri, 28 Aug 2026

Do Wall Street Analysts Like Mettler-Toledo Stock?

Mettler-Toledo has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Yahoo Finance Fri, 21 Aug 2026

Mettler-Toledo (MTD) Upgraded to Buy: Here's Why

Mettler-Toledo (MTD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo Finance Mon, 10 Aug 2026

What Investors Should Know as Mettler-Toledo Insiders Sell Shares After a Strong Quarter

Head of Process Analytics Gerry Keller liquidated stock worth $342,514 on August 3.

Yahoo Finance Mon, 10 Aug 2026

Mettler-Toledo's CFO Cashed In Options After a Strong Quarter. Here's What to Know

Vadala exercised stock options and liquidated the position same-day.

Yahoo Finance Sat, 08 Aug 2026

Mettler-Toledo (MTD) Q2 2026 Earnings Call Transcript

China sales surged 9% as laboratory demand accelerated, lifting full-year guidance.

Yahoo Finance Mon, 10 Aug 2026

What Investors Should Know About a Mettler-Toledo Director's Two Transactions This Past Week

This exercise-and-sell transaction captured a gain on options struck at $397.95.

MTD — Frequently Asked Questions

What is the current share price of Mettler-Toledo International Inc. (MTD)?

As of 2026-09-07 16:24 PDT, Mettler-Toledo International Inc. (MTD) trades at $1,345.26 on NYSE. Its 52-week range is $1,025.53 to $1,506.02.

What is the market capitalisation of MTD?

Mettler-Toledo International Inc. (MTD) has a market capitalisation of $26.95B on NYSE.

What is the P/E ratio of MTD?

MTD trades at a trailing price-to-earnings (P/E) ratio of 30.34. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2,233.53.

Is MTD a good stock to buy?

This page provides a data-driven analysis of Mettler-Toledo International Inc. (MTD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space